Yuki Gosei Kogyo Co Ltd

Yuki Gosei Kogyo maintains a capital structure with a debt-to-equity ratio of 0.64, indicating moderate leverage. The company's liquidity position is characterized by a current ratio of 1.58, suggesting it can cover short-term obligations with its current assets. However, the company's free cash flow is negative at -1.61 billion JPY, and capital expenditures are substantial at -3.34 billion JPY, indicating ongoing investment in operations. Profitability metrics show a return on equity (ROE) of 6.84% and a return on assets (ROA) of 3.33%, which are below the industry median for Diversified Chemicals. The company's gross profit margin is 21.87% (3.31 billion JPY gross profit on 15.13 billion JPY revenue), and its operating margin is 7.62% (1.15 billion JPY operating income on 15.13 billion JPY revenue), both of which are in line with the industry's average but suggest limited pricing power. The company's revenue is derived from multiple segments, including amino acids, chemicals, pharmaceuticals, and contract manufacturing. While the financial data does not specify revenue by segment, the company's geographic exposure is primarily concentrated in Japan, with no disclosed international revenue. This concentration may expose the company to regional economic and regulatory risks. Looking ahead, the company's revenue is expected to remain stable, with no significant growth or decline projected in the current or next fiscal year. The company's operating cash flow of 2.14 billion JPY supports its liquidity, but the negative free cash flow and high capital expenditures suggest ongoing reinvestment in the business. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations without external financing. However, the low dilution risk suggests that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders. Recent filings and transcripts do not indicate any material events or changes in the company's operations or strategy. The company continues to focus on its core businesses in amino acids, chemicals, and pharmaceuticals, with no disclosed major new initiatives or strategic shifts.